Recombinant Anti-EGFR x Anti-IGF1R Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-EGFR antibody variable domain is fused to the C terminal of an IgG of anti-IGF1R antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Colorectal cancer; Cervical cancer; Breast cancer; Pancreatic cancer therapy.